Calliditas Therapeutics AB
STO:CALTX

Watchlist Manager
Calliditas Therapeutics AB Logo
Calliditas Therapeutics AB
STO:CALTX
Watchlist
Price: 208 SEK 0.87% Market Closed
Market Cap: 12.5B SEK
Have any thoughts about
Calliditas Therapeutics AB?
Write Note

Calliditas Therapeutics AB
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Calliditas Therapeutics AB
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Calliditas Therapeutics AB
STO:CALTX
Income from Continuing Operations
-kr480.4m
CAGR 3-Years
8%
CAGR 5-Years
-69%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Income from Continuing Operations
kr266.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Income from Continuing Operations
kr76.2m
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Income from Continuing Operations
-kr177.8m
CAGR 3-Years
-25%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Income from Continuing Operations
-kr21.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Income from Continuing Operations
-kr269.6m
CAGR 3-Years
-44%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
No Stocks Found

Calliditas Therapeutics AB
Glance View

Market Cap
12.5B SEK
Industry
Pharmaceuticals

Calliditas Therapeutics AB clinical-stage biopharmaceutical company. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2018-06-29. The company is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

CALTX Intrinsic Value
725.13 SEK
Undervaluation 71%
Intrinsic Value
Price

See Also

What is Calliditas Therapeutics AB's Income from Continuing Operations?
Income from Continuing Operations
-480.4m SEK

Based on the financial report for Jun 30, 2024, Calliditas Therapeutics AB's Income from Continuing Operations amounts to -480.4m SEK.

What is Calliditas Therapeutics AB's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-69%

Over the last year, the Income from Continuing Operations growth was -64%. The average annual Income from Continuing Operations growth rates for Calliditas Therapeutics AB have been 8% over the past three years , -69% over the past five years .

Back to Top